Your browser doesn't support javascript.
loading
A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice.
Medeiros, Pedro Henrique Q S; Bolick, David T; Ledwaba, Solanka E; Kolling, Glynis L; Costa, Deiziane V S; Oriá, Reinaldo B; Lima, Aldo Ângelo M; Barry, Eileen M; Guerrant, Richard L.
Afiliação
  • Medeiros PHQS; 1Center for Global Health and Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA USA.
  • Bolick DT; 2Institute of Biomedicine, Federal University of Ceará, Fortaleza, CE Brazil.
  • Ledwaba SE; 1Center for Global Health and Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA USA.
  • Kolling GL; 1Center for Global Health and Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA USA.
  • Costa DVS; 3Department of Microbiology, University of Venda, Thohoyandou, Limpopo province South Africa.
  • Oriá RB; 1Center for Global Health and Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA USA.
  • Lima AÂM; 1Center for Global Health and Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA USA.
  • Barry EM; 2Institute of Biomedicine, Federal University of Ceará, Fortaleza, CE Brazil.
  • Guerrant RL; 1Center for Global Health and Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA USA.
NPJ Vaccines ; 5(1): 30, 2020.
Article em En | MEDLINE | ID: mdl-32257392
Vaccine studies for Shigella flexneri and enterotoxigenic Escherichia coli have been impaired by the lack of optimal animal models. We used two murine models to show that a S. flexneri 2a bivalent vaccine (CVD 1208S-122) expressing enterotoxigenic Escherichia coli colonization factor antigen-I (CFA/I) and the binding subunits A2 and B of heat labile-enterotoxin (LTb) is immunogenic and protects against weight loss and diarrhea. These findings document the immunogenicity and pre-clinical efficacy effects of CVD 1208S-122 vaccine and suggest that further work can help elucidate relevant immune responses and ultimately its clinical efficacy in humans.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article